Vir Biotechnology has joined the public markets, raising $142.9 million to support clinical tests of its infectious disease drugs. The San Francisco firm offered 7.1 million shares priced at $20 each, which was the low end of the $20 to $22 range that it had planned. Vir shares are expected to start trading later today … Continue reading “Vir Bio’s IPO Brings In $143M for Tests of Hepatitis B Drug and More”
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
Ra Pharmaceuticals, whose lead autoimmune disease drug candidate is viewed as a potential alternative to one of the most expensive medicines in the world, is being acquired by Belgian pharmaceuticals giant UCB in a $2.1 billion deal. According to terms announced Thursday, UCB will pay $48 in cash for each Ra Pharma share. That’s a … Continue reading “UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma”
Jazz Pharma’s Matthew Young to Join Grail as COO & CFO
Matthew Young has been appointed chief operating officer and chief financial officer of Grail. He will start his new job at the Menlo Park, CA-based liquid biopsy developer on Oct. 28. Young is coming to Grail from Jazz Pharmaceuticals (NASDAQ: [[ticker:JAZZ]]), where he is executive vice president and chief financial officer. His new appointment is … Continue reading “Jazz Pharma’s Matthew Young to Join Grail as COO & CFO”
Cue Biopharma Promotes Suri to President, Passeri Keeps CEO Role
Cue Biopharma (NASDAQ: [[ticker:CUE]]) has promoted Anish Suri to president in addition to his current duties as chief scientific officer. The additional role gives him oversight of the Cambridge, MA-based company’s corporate functions. The promotion means that Daniel Passeri’s role as president and CEO changes to only chief executive. Before joining Cue last year, Suri … Continue reading “Cue Biopharma Promotes Suri to President, Passeri Keeps CEO Role”
BioMarin Promotes Lon Cardon to Chief Scientific Strategy Officer
Lon Cardon, who has served as chief scientific officer at BioMarin Pharmaceutical (NASDAQ: [[ticker:BMRN]]) the past two years, has been promoted to a newly created position: chief scientific strategy officer. San Rafael, CA-based BioMarin says in the new role Cardon will be responsible for building the company’s drug pipeline. Before joining BioMarin, Cardon worked at … Continue reading “BioMarin Promotes Lon Cardon to Chief Scientific Strategy Officer”
Tempest Therapeutics Taps Stephen Brady for Chief Operating Officer
Stephen Brady has been appointed president and chief operating officer of Tempest Therapeutics. Brady was most recently executive vice president of strategy and finance at Immune Design, which was acquired by Merck (NYSE: [[ticker:MRK]]) earlier this year. South San Francisco-based Tempest, a spinout of venture capital firm Versant Ventures, raised $70 million in Series B … Continue reading “Tempest Therapeutics Taps Stephen Brady for Chief Operating Officer”
Genentech’s Merdad Parsey to Join Gilead as Chief Medical Officer
Merdad Parsey has been appointed chief medical officer of Gilead Sciences (NASDAQ: [[ticker:GILD]]). The Foster City, CA-based company said Parsey will start his new role on Nov. 1. He will join Gilead from Roche subsidiary Genentech, where he is senior vice president of early clinical development in the company’s Research and Early Development Group. His … Continue reading “Genentech’s Merdad Parsey to Join Gilead as Chief Medical Officer”
Verve Therapeutics Names Lyndra’s Bellinger Chief Scientific Officer
Verve Therapeutics has appointed Andrew Bellinger to serve as its chief scientific officer, the same position he held at Lyndra Therapeutics. Bellinger, who is a general cardiologist at Brigham and Women’s Hospital, will continue to serve as an advisor to Lyndra. His experience also includes positions at Cocoon Biotech. Verve is developing a way to … Continue reading “Verve Therapeutics Names Lyndra’s Bellinger Chief Scientific Officer”
With $65M, Cygnal Tunes In to Nerve Signals for Drug-Making Clues
The peripheral nervous system traverses the body, connecting the brain and spinal cord to distant organs and limbs similar to the way a fiber optic network connects an Internet provider to a computer user at a far-flung home. But peripheral nerves also communicate with disease cells, according to Cygnal Therapeutics CEO Pearl Huang. Understanding this … Continue reading “With $65M, Cygnal Tunes In to Nerve Signals for Drug-Making Clues”
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
Oxygen’s importance in cellular processes has long been known. But the work to understand how cells sense and adapt to changes in oxygen levels has led to medical insights and potential treatments for anemia, cancer, and more—and today, it has turned into the 2019 Nobel Prize in Medicine. William Kaelin Jr., Sir Peter Ratcliffe, and … Continue reading “Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels”
Vertex Pharma Promotes Bozic as Kewalramani’s Successor
Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]) has appointed Carmen Bozic to serve as executive vice president of global medicines development and medical affairs. Bozic joined Boston-based Vertex earlier this year as senior vice president and head of global clinical development. Bozic will take on additional responsibilities as Vertex’s chief medical officer on April 1 when current CMO Reshma … Continue reading “Vertex Pharma Promotes Bozic as Kewalramani’s Successor”
Nektar Promotes Zalevsky to Chief R&D Officer, Labrucherie to COO
Nektar Therapeutics (NASDAQ: [[ticker:NKTR]]) has promoted Jonathan Zalevsky to chief research and development officer. Zalevsky joined the San Francisco drug developer in 2015 and has been its chief scientific officer since 2017. Nektar also announced that Gil Labrucherie has been promoted to chief operating officer in addition to his duties as chief financial officer. Nektar’s … Continue reading “Nektar Promotes Zalevsky to Chief R&D Officer, Labrucherie to COO”
Three Biotechs Raise $320M in IPOs, Two Others Pass on Wall Street
With five biotech IPOs on the calendar, this week was expected to be a big one. Three companies ended up making Wall Street debuts, raising a combined $320 million, led by Viela Bio. But two other firms didn’t like the market conditions and decided against going public for now. Here’s a recap of the week’s … Continue reading “Three Biotechs Raise $320M in IPOs, Two Others Pass on Wall Street”
Icosavax Lands $51M to Bring Vaccine for Respiratory Virus to Clinic
Many vaccines are made from either a weakened virus or a protein taken from a virus. But so far, scientists haven’t had much luck developing such vaccines for respiratory syncytial virus (RSV), which causes an infection that is typically mild but can become deadly in infants and older adults. Icosavax is taking a different route … Continue reading “Icosavax Lands $51M to Bring Vaccine for Respiratory Virus to Clinic”
Viscient Bio Proposes Organovo Merger to Tackle NASH and Go Beyond
[Updated 5:58 p.m. PT. See below.] Organovo, a company developing technology to 3D print human tissue, announced two months ago that its dwindling cash is leading it to explore options that include merging with another firm. The San Diego biotech now has an offer from a familiar face close to home. Viscient Biosciences, a seven-person … Continue reading “Viscient Bio Proposes Organovo Merger to Tackle NASH and Go Beyond”
Bayer and Arvinas Appoint John Dombrosky CEO of Joint Venture Oerth
The Bayer and Arvinas (NASDAQ: [[ticker:ARVN]]) joint venture announced in July now has a name and a chief executive. Oerth Bio (pronounced “Earth”) will be led by CEO John Dombrosky. Dombrosky joins Oerth from Agtech Accelerator, where he has been CEO for the past three years. His experience also includes roles at Syngenta, Thomson Reuters, … Continue reading “Bayer and Arvinas Appoint John Dombrosky CEO of Joint Venture Oerth”
Dyne Appoints Brumm President & CEO, Subramanian Shifts to CSO
Joshua Brumm has been appointed president and CEO of Dyne Therapeutics. Romesh Subramanian, Dyne’s founder and former CEO, has shifted to a new role as chief scientific officer. Brumm will join Waltham, MA-based Dyne from Kaleido Biosciences (NASDAQ: [[ticker:KLDO]]), where he has been chief financial officer since last year. Kaleido said Brumm’s last day will … Continue reading “Dyne Appoints Brumm President & CEO, Subramanian Shifts to CSO”
Sangamo Taps Cytokinetics Exec Cockroft for Chief Medical Officer
Sangamo Therapeutics (NASDAQ: [[ticker:SGMO]]) has appointed Bettina Cockroft to serve as senior vice president and chief medical officer. Cockroft comes to Brisbane, CA-based Sangamo from Cytokinetics (NASDAQ: [[ticker:CYTK]]), where she was vice president of clinical research, neurology. Her experience also includes positions at Merck Serono, Novartis Consumer Health, and Menarini Ricerche. In July, Sangamo and … Continue reading “Sangamo Taps Cytokinetics Exec Cockroft for Chief Medical Officer”
Biogen’s Ehlers Leaving for Apple Tree, Steps Into Limelight as CEO
Michael Ehlers, Biogen’s executive vice president of research and development, is leaving for a job in venture capital and an opportunity to lead a gene therapy startup. Ehlers has been appointed chief scientific officer and venture partner of New York-based Apple Tree Partners. He’ll also become CEO of one of the firm’s portfolio companies, Limelight … Continue reading “Biogen’s Ehlers Leaving for Apple Tree, Steps Into Limelight as CEO”
Dova Pharmaceuticals Agrees to Sobi Acquisition, Shares Jump 38%
In the past three years, Dova Pharmaceuticals has completed a company launch, gone public, and won its first drug approval. Now the biotech is in line to be acquired by Swedish Orphan Biovitrum (Sobi). According to deal terms announced Monday, Dova (NASDAQ: [[ticker:DOVA]]) stockholders will receive $27.50 per share up front, a 36 percent premium … Continue reading “Dova Pharmaceuticals Agrees to Sobi Acquisition, Shares Jump 38%”
Beam Therapeutics Preps IPO and Sheds Light on Its Gene-Editing Drugs
A number of gene-editing companies have joined the public markets in recent years. Beam Therapeutics, which is developing a CRISPR-based technology intended to offer even more precise genomic edits, aims to become the latest one. Cambridge, MA-based Beam filed its IPO paperwork with securities regulators late Friday. The company set a preliminary $100 million target … Continue reading “Beam Therapeutics Preps IPO and Sheds Light on Its Gene-Editing Drugs”
Genfit Promotes Dean Hum to President as it Preps US NASH Plans
Genfit (NASDAQ: [[ticker:GNFT]]) has promoted Dean Hum to president in addition to his duties as chief operating officer. The France-based company said Hum will relocate to its Cambridge, MA, office. Hum joined Genfit in 2000 as chief scientific officer. He became chief operating officer last year. Genfit is one of a growing number of biotechs … Continue reading “Genfit Promotes Dean Hum to President as it Preps US NASH Plans”
Kaleido Exec Brumm Is Stepping Down to Become CEO of Another Biotech
Joshua Brumm, chief operating and chief financial officer of Kaleido Biosciences (NASDAQ: [[ticker:KLDO]]) since last year, will step down on Oct. 11. Lexington, MA-based Kaleido said that Brumm is leaving to become president and CEO of an undisclosed biotechnology company. Richard Scalzo, Kaleido’s corporate controller, has been appointed principal accounting officer and will assume some … Continue reading “Kaleido Exec Brumm Is Stepping Down to Become CEO of Another Biotech”
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
Lung injuries linked to electronic cigarettes have topped 800 cases, including 12 deaths, according to the Centers for Disease Control and Prevention. Public health officials aren’t sure whether the injuries are from legally sold products made by companies such as Juul, or from black-market items such as those that allow users to “vape” the active … Continue reading “Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More”
Hookipa Pharma Names Christine Baker CBO, Roman Necina CTO
Christine Baker has joined Hookipa Pharma (NASDAQ: [[ticker:HOOK]]) as chief business officer, the same position she held at EpicentRx. New York-based Hookipa also appointed Roman Necina chief technology officer. Necina, who is currently a senior vice president for technical development and chief strategist at Takeda Pharmaceutical (NYSE: [[ticker:TAK]]), will start at Hookipa in November. The … Continue reading “Hookipa Pharma Names Christine Baker CBO, Roman Necina CTO”
Catabasis Names Ex-Alkermes Exec Komjathy Chief Commercial Officer
Andrew Komjathy has been appointed chief commercial officer of Catabasis Pharmaceuticals (NASDAQ: [[ticker:CATB]]). He joins the Cambridge, MA, drug developer from Alkermes (NASDAQ: [[ticker:ALKS]]), where he was vice president of commercial sales. His experience also includes positions at Genzyme, Shire, and Biogen (NASDAQ: [[ticker:BIIB]]). Catabasis has changed its therapeutic focus several times , having pursued drugs … Continue reading “Catabasis Names Ex-Alkermes Exec Komjathy Chief Commercial Officer”
Forma Therapeutics Adds Kelly, Shegog, and Wadlinger to C-Suite
Forma Therapeutics has promoted Patrick Kelly to senior vice president and chief medical officer. Kelly previously led translational clinical activities for Watertown, MA-based Forma. In other moves, Mary Wadlinger was promoted from senior vice president of human resources to senior vice president of corporate affairs and chief human resources officer. Forma also named Todd Shegog … Continue reading “Forma Therapeutics Adds Kelly, Shegog, and Wadlinger to C-Suite”
Concert Pharma Names Ex-Merrimack Exec Munsie Chief Legal Officer
Concert Pharmaceuticals (NASDAQ: [[ticker:CNCE]]) has appointed Jeffrey Munsie to serve as its chief legal officer. Munsie was most recently senior vice president, general counsel, and head of corporate operations at Merrimack Pharmaceuticals (NASDAQ: [[ticker:MACK]]). Earlier this month, Lexington, MA-based Concert released positive Phase 2 data for CTP-543, an experimental treatment for hair loss caused by … Continue reading “Concert Pharma Names Ex-Merrimack Exec Munsie Chief Legal Officer”
Amgen’s Galimi Jumps to Adicet Bio to Become Chief Medical Officer
Francesco Galimi has been appointed senior vice president and chief medical officer of Adicet Bio. Galimi comes to the Menlo Park, CA-based cancer drug developer from Amgen (NASDAQ: [[ticker:AMGN]]), where he was global program general manager of early development. His experience also includes positions at Onyx Pharmaceuticals and the Genomics Institute of the Novartis Research … Continue reading “Amgen’s Galimi Jumps to Adicet Bio to Become Chief Medical Officer”
Omega Therapeutics Taps Ex-Macrolide Pharma Exec Karande for CEO
Mahesh Karande has been appointed CEO of Omega Therapeutics. Karande was most recently president and CEO of Macrolide Pharmaceuticals. His experience also includes positions at Novartis (NYSE: [[ticker:NVS]]). Cambridge, MA-based Omega, which was formed by venture capital firm Flagship Pioneering, is developing drugs based on epigenetics, the study of the biological mechanisms that turn genes … Continue reading “Omega Therapeutics Taps Ex-Macrolide Pharma Exec Karande for CEO”
Akcea Shakes Up Management and Shows Three Executives the Door
Akcea Therapeutics has already been struggling to turn its two products into commercial winners. Now it will have to do so during a massive management transition. Akcea (NASDAQ: [[ticker:AKCA]]) said Monday that CEO Paula Soteropoulos, president Sarah Boyce and chief operating officer Jeff Goldberg have left the company. Akcea’s board of directors has appointed Damien … Continue reading “Akcea Shakes Up Management and Shows Three Executives the Door”
An Entrepreneur’s Quest to Make Seattle a Genome Sciences Hub
Ivan Liachko turned postdoctoral research at the University of Washington into a company whose genomics tools are now found in laboratories researching human, animal, and plant health. His firm, Phase Genomics, was one of the first startups to come out of UW’s genome sciences department. As a first-time entrepreneur working from UW’s incubator more than … Continue reading “An Entrepreneur’s Quest to Make Seattle a Genome Sciences Hub”
Five Prime’s Knickerbocker Resigns, Director Ringo Named Interim CEO
Aron Knickerbocker, CEO of Five Prime Therapeutics (NASDAQ: [[ticker:FPRX]]), has resigned “to pursue new challenges and opportunities,” the company announced after the market close Thursday. Knickerbocker was promoted to CEO nearly two years ago to succeed founder and longtime CEO Lewis “Rusty” Williams, who became the South San Francisco biotech’s executive chairman. Five Prime said … Continue reading “Five Prime’s Knickerbocker Resigns, Director Ringo Named Interim CEO”
SR One’s Roberts Tapped as Chief Scientific Officer of Black Diamond
Christopher Roberts has been appointed chief scientific officer of Cambridge, MA-based Black Diamond Therapeutics. Roberts was most recently entrepreneur in residence at SR One, the investment arm of GlaxoSmithKline (NYSE: [[ticker:GSK]]). Roberts’s experience also includes positions at Syros Pharmaceuticals and GSK. Roberts is succeeding Alex Mayweg of venture capital firm Versant Ventures, a Black Diamond … Continue reading “SR One’s Roberts Tapped as Chief Scientific Officer of Black Diamond”
CymaBay Chief Medical Officer Boudes to Depart at September’s End
CymaBay Therapeutics (NASDAQ: [[ticker:CBAY]]) announced that Pol Boudes, the company’s chief medical officer since 2014, will step down at the end of the month. No reason for Boudes’s departure was given, but CymaBay said in a regulatory filing that the decision was mutual. A search for a successor is underway. Newark, CA-based CymaBay is developing … Continue reading “CymaBay Chief Medical Officer Boudes to Depart at September’s End”
Gemini Therapeutics Picks Orchard’s Jason Meyenburg for CEO
Jason Meyenburg has been appointed CEO of Gemini Therapeutics. He is also joining the Cambridge, MA, company’s board of directors. Meyenburg was most recently chief commercial officer of Orchard Therapeutics (NASDAQ: [[ticker:ORTX]]), a job he left last week. His experience also includes positions at Vtesse Pharmaceuticals, Sucampo Pharmaceuticals, and Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]). In 2017, … Continue reading “Gemini Therapeutics Picks Orchard’s Jason Meyenburg for CEO”
Foghorn Therapeutics Adds Samuel Agresta, Allan Reine to C-Suite
Samuel Agresta has been appointed chief medical officer of Cambridge, MA-based Foghorn Therapeutics. Agresta stepped down as the chief medical officer of Infinity Pharmaceuticals last month but remains on that company’s board of directors. His experience also includes positions at Agios Pharmaceuticals, Genentech, and the University of South Florida’s Moffit Cancer Center. In other moves, … Continue reading “Foghorn Therapeutics Adds Samuel Agresta, Allan Reine to C-Suite”
Retrophin’s Neil McFarlane Named Adamas CEO, Succeeding Gregory Went
Adamas Pharmaceuticals (NASDAQ: [[ticker:ADMS]]) appointed Neil McFarlane to serve as its new CEO. He is also joining the Emeryville, CA, company’s board of directors. McFarlane succeeds Gregory Went, chairman and CEO of Adamas since its inception. Went is stepping down from the board but he will continue to advise the company. McFarlane was most recently … Continue reading “Retrophin’s Neil McFarlane Named Adamas CEO, Succeeding Gregory Went”
High-Flying Ginkgo Nets Another $290M to Program Cells Like Computers
Ginkgo Bioworks, a synthetic biology specialist that has become worth billions, has raised another $290 million to expand the breadth of a technology that tinkers with a cell’s genetic code and reprograms it—like programming a computer. Boston-based Ginkgo uses a combination of software and robotic systems to design organisms. It started out making microbes engineered … Continue reading “High-Flying Ginkgo Nets Another $290M to Program Cells Like Computers”
Advisory Body Backs Aimmune Peanut Allergy Drug, Next Up: the FDA
A panel of independent advisors to the FDA voted on Friday to recommend approval of an experimental peanut allergy drug from Aimmune Therapeutics. But concern about the risks of an allergic reaction to the therapy led the committee of mostly physicians to also recommend a safety plan to ensure that clinicians, patients, and their families … Continue reading “Advisory Body Backs Aimmune Peanut Allergy Drug, Next Up: the FDA”
BACEless: Eisai, Biogen Pull Plug on Alzheimer’s Drug in Final Stage
Add another once-promising Alzheimer’s disease drug to the scrap heap. Eisai and Biogen (NASDAQ: [[ticker:BIIB]]) are halting a Phase 3 test after an independent safety review concluded the risks of experimental Alzheimer’s drug elenbecestat outweigh the benefits. The companies did not explain what the independent board found. Some drugs that work the same way have … Continue reading “BACEless: Eisai, Biogen Pull Plug on Alzheimer’s Drug in Final Stage”
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
Wall Street welcomed three life science companies to the public markets this week. 10x Genomics led the way Wednesday, followed by SpringWorks Therapeutics and Satsuma Pharmaceuticals on Thursday. Combined, the three companies raised more than $595 million from their IPOs. According to IPO research firm Renaissance Capital, 153 companies have filed the paperwork this year … Continue reading “SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M”
FDA Doesn’t Shell Peanut Allergy Drug Pre-Hearing, Aimmune Shares Climb
Peanut allergy sufferers know they need to stay away from certain foods that can put them in danger. But what about accidental exposure? Even trace amounts of peanut protein in their food or someone else’s can trigger an allergic reaction that sends them to the hospital. That’s what makes Palforzia, an experimental peanut allergy treatment … Continue reading “FDA Doesn’t Shell Peanut Allergy Drug Pre-Hearing, Aimmune Shares Climb”
BlackThorn Therapeutics Names Monique Levy Chief Strategy Officer
Monique Levy has been appointed chief strategy officer of BlackThorn Therapeutics. Levy most recently worked at iCarbonX as global head of strategy and partnerships. Her experience also includes positions at PatientsLikeMe and Decision Resources Group. San Francisco-based BlackThorn is using artificial intelligence to help develop psychiatric drugs. In June, the company raised $76 million in … Continue reading “BlackThorn Therapeutics Names Monique Levy Chief Strategy Officer”
Challenging CRISPR, Trucode Raises $34M for New Gene-Editing System
Gene-editing technology offers the potential to treat inherited disorders with selective edits and corrections to an afflicted individual’s genetic code. But with such molecular tinkering comes with the risk of unintended changes to the genome. Biotech startup Trucode Gene Repair is developing technology that it claims can edit genes in a way that reduces the … Continue reading “Challenging CRISPR, Trucode Raises $34M for New Gene-Editing System”
Genfit Names Carol Addy to Chief Medical Officer Role
Carol Addy has been appointed chief medical officer of France-based Genfit (NASDAQ: [[ticker:GNFT]]). She will be based at the company’s Cambridge, MA, office. Addy, an endocrinologist, was most recently the chief medical officer of Merck (NYSE: [[ticker:MRK]]) subsidiary Health Management Resources. Genfit’s lead drug candidate, elafibranor, is currently in late-stage testing as a treatment for … Continue reading “Genfit Names Carol Addy to Chief Medical Officer Role”
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
Hearing loss affects millions of Americans but to date, there are no FDA-approved medicines to treat them. Frequency Therapeutics is developing a hearing loss drug that taps into the body’s regenerative capabilities. As the company prepares to advance the experimental treatment to mid-stage studies, it is planning an IPO to finance the research. Frequency set … Continue reading “Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds”
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
Being first to market with a new type of drug brings advantages. The first mover sets the bar for what physicians, payers, and patients can expect of that medicine and how much it costs. It grabs market share that followers have to steal away. But the first mover isn’t infallible if someone else has something … Continue reading “Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone”
Novartis & IFM Team Up Again, With Buyout Option for Autoimmune R&D
IFM Therapeutics has lined up another pact with a big pharma company, and it’s the second one in less than a year with Novartis. Boston-based IFM Therapeutics announced Thursday that Novartis (NYSE: [[ticker:NVS]]) has agreed to pay the research and development costs of IFM Due, a subsidiary developing immunotherapies for inflammatory and autoimmune diseases. Novartis … Continue reading “Novartis & IFM Team Up Again, With Buyout Option for Autoimmune R&D”
Synlogic’s C-Suite Adds Richard Riese, CFO Todd Shegog to Depart
Synlogic (NASDAQ: [[ticker:SYBX]]) has appointed Richard Riese to serve as chief medical officer. Riese was most recently vice president of clinical development at Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]). In other moves, Synlogic announced that Todd Shegog, the company’s chief financial officer, will leave on Sept. 18 to pursue another opportunity. In a securities filing, Synlogic said … Continue reading “Synlogic’s C-Suite Adds Richard Riese, CFO Todd Shegog to Depart”